The small molecule inhibitor SU056-mediated targeting of YB1 inhibits the Rb pathway in triple-negative breast cancer tumors
- 1The MetroHealth System, Case Western Reserve University School of Medicine
Abstract
Background: Triple-negative breast cancer (TNBC) tumors lack expression of estrogen receptor (ER), progesterone receptor (PR), and HER2, limiting the availability of targeted therapeutic options. As a result, TNBC is characterized by a high propensity for metastasis, rapid recurrence, and poor overall prognosis. Despite significant research efforts, the molecular mechanisms that drive TNBC progression and metastasis remain incompletely understood.Y-box binding protein-1 (YB1) is a multifunctional DNA/RNA-binding protein that regulates transcription, translation, and mRNA stability. Aberrant activation of YB1 has been implicated in multiple oncogenic processes, including proliferation, survival, invasion, metastasis, and therapy resistance in several cancer types, including TNBC. Our investigations have revealed a central role for YB1 in regulating key hallmarks of cancer that drive TNBC tumor progression and metastatic dissemination. Methods: Cell viability and drug sensitivity in TNBC cell lines were assessed using the MTT assay to determine IC₅₀ values for pharmacologic inhibitors. Western blotting and quantitative RT-PCR were used to quantify protein and mRNA expression levels in TNBC cell lines and tumor samples. Oncogenic phenotypes were evaluated using 2D colony formation assays, 3D tumorsphere growth assays, limiting dilution, and transwell migration assays to assess proliferative, stem-like, and migratory capacities. Cell cycle progression was analyzed using flow cytometry-based assays. In vivo therapeutic efficacy was evaluated using preclinical xenograft and patient-derived xenograft (PDX) mouse models of TNBC to assess tumor growth and metastatic progression following treatment. Results: Our studies demonstrate that the small-molecule inhibitor SU056, which specifically targets YB1 for degradation, significantly suppresses the oncogenic behavior of TNBC cell lines and tumors. Pharmacologic inhibition of YB1 reduced TNBC cell proliferation, clonogenic growth, tumorsphere formation, stemness and migratory capacity. Importantly, combined treatment with SU056 and the CDK4/6 inhibitor palbociclib enhanced the inhibitory effect on TNBC cell growth and tumor progression compared with either agent alone. Mechanistically, both genetic and pharmacologic targeting of YB1 suppressed TNBC tumor growth and metastatic potential through modulation of the Cyclin D/CDK4/6/Rb signaling axis, leading to inhibition of cell cycle progression and induction of G1 arrest. Conclusion: -TNBC.
Related
- PFN1 inhibits lytic replication of Kaposi sarcoma-associated herpesvirus through SQSTM1/p62-mediated selective autophagy targeting the KSHV helicase
- Targeting SLC1A5-mediated glutamine metabolism overcomes PARP inhibitor resistance in ovarian cancer.
- A First-in-Class, Brain-Penetrant Small Molecule Inhibitor of the NOS1AP-Tau Interaction Rescues Tau Pathology In Vivo and Improves Cognition
- 563 Updated safety and efficacy of AN4005, an oral small-molecule PD-L1 inhibitor, in advanced solid tumors: phase I dose-escalation and expansion
- Targeting P2Y₁₄R inhibits proliferation of cervical cancer cells and organoids and activates cAMP/PKA/CREB signaling pathway.
BibTeX
@misc{wang2026small,
title = {{The small molecule inhibitor SU056-mediated targeting of YB1 inhibits the Rb pathway in triple-negative breast cancer tumors}},
author = {W. Wang and Y. Kim and X. Zhao and K. W. Bonk and R. Keri and B. Su and K. Sossey-Alaoui},
howpublished = {bioRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.05.749600},
url = {https://www.biorxiv.org/content/10.64898/2026.09.05.749600v1},
note = {Public domain},
}
RIS
TY - UNPB
TI - The small molecule inhibitor SU056-mediated targeting of YB1 inhibits the Rb pathway in triple-negative breast cancer tumors
AU - W. Wang
AU - Y. Kim
AU - X. Zhao
AU - K. W. Bonk
AU - R. Keri
AU - B. Su
AU - K. Sossey-Alaoui
PY - 2026
DA - 2026/09/05
PB - bioRxiv
DO - 10.64898/2026.09.05.749600
UR - https://www.biorxiv.org/content/10.64898/2026.09.05.749600v1
AB - Background: Triple-negative breast cancer (TNBC) tumors lack expression of estrogen receptor (ER), progesterone receptor (PR), and HER2, limiting the availability of targeted therapeutic options. As a result, TNBC is characterized by a high propensity for metastasis, rapid recurrence, and poor overall prognosis. Despite significant research efforts, the molecular mechanisms that drive TNBC progression and metastasis remain incompletely understood.Y-box binding protein-1 (YB1) is a multifunctional DNA/RNA-binding protein that regulates transcription, translation, and mRNA stability. Aberrant activation of YB1 has been implicated in multiple oncogenic processes, including proliferation, survival, invasion, metastasis, and therapy resistance in several cancer types, including TNBC. Our investigations have revealed a central role for YB1 in regulating key hallmarks of cancer that drive TNBC tumor progression and metastatic dissemination. Methods: Cell viability and drug sensitivity in TNBC cell lines were assessed using the MTT assay to determine IC₅₀ values for pharmacologic inhibitors. Western blotting and quantitative RT-PCR were used to quantify protein and mRNA expression levels in TNBC cell lines and tumor samples. Oncogenic phenotypes were evaluated using 2D colony formation assays, 3D tumorsphere growth assays, limiting dilution, and transwell migration assays to assess proliferative, stem-like, and migratory capacities. Cell cycle progression was analyzed using flow cytometry-based assays. In vivo therapeutic efficacy was evaluated using preclinical xenograft and patient-derived xenograft (PDX) mouse models of TNBC to assess tumor growth and metastatic progression following treatment. Results: Our studies demonstrate that the small-molecule inhibitor SU056, which specifically targets YB1 for degradation, significantly suppresses the oncogenic behavior of TNBC cell lines and tumors. Pharmacologic inhibition of YB1 reduced TNBC cell proliferation, clonogenic growth, tumorsphere formation, stemness and migratory capacity. Importantly, combined treatment with SU056 and the CDK4/6 inhibitor palbociclib enhanced the inhibitory effect on TNBC cell growth and tumor progression compared with either agent alone. Mechanistically, both genetic and pharmacologic targeting of YB1 suppressed TNBC tumor growth and metastatic potential through modulation of the Cyclin D/CDK4/6/Rb signaling axis, leading to inhibition of cell cycle progression and induction of G1 arrest. Conclusion: -TNBC.
ER -